Prediction by quantitative histology of pathological stage in prostate cancer

• DOI: 10.1016/j.ejso.2004.12.002
• Publication Date: 2005-01-25T18:14:04Z
• Authors: P. Pepe; A. Galia; F. Fraggetta; G. Grasso; R. Allegro; F. Aragona
• Keywords: Male; Biopsy; Prostatic Neoplasms; Middle Aged; Prostate-Specific Antigen; Sensitivity and Specificity; 3. Good health; 03 medical and health sciences; Logistic Models; 0302 clinical medicine; ROC Curve; Predictive Value of Tests; Multivariate Analysis; Odds Ratio; Humans; Aged; Neoplasm Staging

To find a predictor of extraprostatic extension in clinically localized prostate cancer (PCa), pre-operative ultrasound-guided prostate needle biopsies and clinico-pathological data were reviewed.One hundred and eighty-three consecutive patients who underwent radical retropubic prostatectomy for clinical T1-T2 PCa and serum PSA <10 ng/ml were reviewed. Pre-operative biopsy was performed according to an extended protocol and whole-mount prostatectomy specimens were processed. The following biopsy variables were categorized to this analysis: Gleason score (< or =6, >6), TPC (< or =20%; >20%), GPC (< or =50%; >50%), cancer-positive cores (< or =2; >2), cancer-positive cores in both lateral portions (yes; no), PCa (monolateral; bilateral).Only 60/183 specimens showed an organ-confined PCa; the remaining ones showed pT3a in 57 cases, pT3b in 11 and pT3 with positive surgical margins in 55. A locally advanced PCa was found in 60.2 and 76.8% of T1c and T2 clinical stage, respectively. The positive predictive value and negative predictive value of biopsy findings to predict a locally advanced PCa was 89.9 and 75%, respectively. All biopsy variables associations were statistically significant; however, among these variables (non-categorized), in multivariate logistic regression analysis, only GPC was significantly associated with pathologic stage (odds ratio estimate was 1.075, 95% CI: 1.053-1.098).Quantitative histology, especially GPC, seems to be helpful for pre-operative staging of PCa in patients with T1c-T2 clinical stage and PSA < 10 ng/ml.